Further studies are warranted to assess the potential use of NGR-TNF (or its more stable and homogeneous derivative S-NGR-TNF), in combination with chemo/immunotherapy, for the treatment of other primary and secondary brain tumors, such as glioblastoma multiforme and brain metastases of breast and lung cancer. This evidence concerns the gene RTN4R and lung cancer.